Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals

Archives of Internal Medicine

Volumn 170, Issue 18, 2010, Pages 1622-1631

  Clarke, Robert ^a   Halsey, Jim ^a   Lewington, Sarah ^a   Lonn, Eva ^b   Armitage, Jane ^a   Manson, JoAnn E ^c   Bønaa, Kaare H ^e   Spence, J David ^f   Nygård, Ottar ^g   Jamison, Rex ^h   Gaziano, J Michael ^d   Guarino, Peter ⁱ   Bennett, Derrick ^a   Mir, Fraz ^j   Peto, Richard ^a   Collins, Rory ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MCMASTER UNIVERSITY   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^f ROBARTS RESEARCH INSTITUTE   (Canada)

^g UNIVERSITY OF BERGEN   (Norway)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^j ADDENBROOKE S HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; PLACEBO; VITAMIN B GROUP;

ADULT; AGED; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVASCULARIZATION; REVIEW; STROKE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CONFIDENCE INTERVALS; DIETARY SUPPLEMENTS; FOLIC ACID; HOMOCYSTEINE; HUMANS; INCIDENCE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TREATMENT FAILURE; VITAMIN B COMPLEX;

EID: 77957949167     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.348     Document Type: Review

References (44)

1. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease.NEngl J Med. 1991;324(17):1149-1155.
2. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274(13):1049- 1057.
3. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk. 1998;5(4):229-232. (Pubitemid 29030108)
4. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288(16):2015-2022. (Pubitemid 35204692)
5. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56(1):111-128.
6. Yap S, Naughten ER, Wilcken B, Wilcken DE, Boers GH. Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy. Semin Thromb Hemost. 2000;26(3):335-340.
7. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr. 2005;82(4):806-812.
8. Baker F, Picton D, Blackwood S, et al. Blinded comparison of folic acid and placebo in patients with ischaemic heart disease: an outcome trial [abstract]. Circulation. 2002;106(suppl 2):741S.
9. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291(5):565-575.
10. Bønaa KH, Njølstad I, Ueland PM, et al; NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578-1588.
11. Lonn E, Yusuf S, Arnold MJ, et al; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B-vitamins in vascular disease [published correction appears in N Engl J Med. 2006;355(7):746]. N Engl J Med. 2006;354(15):1567-1577.
12. Jamison RL, Hartigan P, Kaufman JS, et al; Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial [published correction appears in JAMA. 2008;300(2)170]. JAMA. 2007;298(10):1163-1170.
13. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299(17):2027-2036.
14. Ebbing M, Bleie Ø, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300(7):795-804.
15. 12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA. 2010;303(24):2486-2494.
16. VITATOPS Trial Study Group; Hankey GJ, Algra A, Chen C, et al. VITATOPS, the Vitamins to Prevent Stroke Trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444). Int J Stroke. 2007;2(2):144-150. (Pubitemid 46691714)
17. Bostom AG, Carpenter MA, Hunsicker L, et al; FAVORIT Study Investigators. Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial. Am J Kidney Dis. 2009;53(1):121-128.
18. Galan P, Briancon S, Blacher J, Czernichow S, Hercberg S. The SU.FOL.OM3 Study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics. Trials. 2008;9:35. doi:10.1186/1745-6215-9-35.
19. China Stroke Primary Prevention Trial. http://clinicaltrials.gov/ct2/ results?term=NCT00794885. Accessed June 1, 2010.
20. B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006;151(2):282-287.
21. Clarke R, Armitage J, Lewington S, Collins R; B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis. Clin Chem Lab Med. 2007;45(12):1575-1581.
22. Early Breast Cancer Trialists' Collaborative Group. Worldwide Evidence 1985-1990. Oxford, England: Oxford University Press; 1990. Treatment of Early Breast Cancer; vol 1.
23. Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J. 1985;6(7):556-585. (Pubitemid 15046383)
24. Yang Q, Botto LD, Erickson JD, et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation. 2006;113(10):1335-1343.
25. Whitlock G. Trends in national mortality rates. http://www.mortality- trends.org. Accessed June 1, 2010.
26. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369(9576):1876-1882. (Pubitemid 46829358)
27. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol. 2007;6(9):830-838. (Pubitemid 47241275)
28. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-1535.
29. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published corrections appear in Lancet. 2005;366(9494):1358 and 2008;371(9630)2084]. Lancet. 2006;366(9493):1267-1278.
30. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA. 2006;296(22):2720-2726. (Pubitemid 44917549)
31. Bazzano LA. Folic acid supplementation and cardiovascular disease: the state of the art. Am J Med Sci. 2009;338(1):48-49.
32. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr. 2002;132(8)(suppl):2350S-2355S.
33. Larsson SC, Giovannucci E, Wolk A. Folate and risk of breast cancer: ameta-analysis. J Natl Cancer Inst. 2007;99(1):64-76.
34. Kim YI. Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr. 2004;80(5):1123-1128.
35. Mason JB, Dickstein A, Jacques PF, et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2007;16(7):1325-1329. (Pubitemid 47076861)
36. Cole BF, Baron JA, Sandler RS, et al; Polyp Prevention Study Group. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007;297(21):2351-2359.
37. Figueiredo JC, Grau MV, Haile RW, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst. 2009;101(6):432-435.
38. Logan RFA, Grainge MJ, Shepherd VC, Armitage NC, Muir KR; ukCAP Trial Group. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008;134(1):29-38. (Pubitemid 350309319)
39. Wu K, Plarz EA, Willett WC, et al. A randomized trial of folic acid supplementation and risk of recurrent colorectal adenoma. Am J Clin Nutr. 2009;90(6):1623-1631.
40. 12. JAMA. 2009;302(19):2119-2126.
41. Bailey RL, Dodd KW, Gahche JJ, et al. Total folate and folic acid intake from foods and dietary supplements in the United States: 2003-2006. Am J Clin Nutr. 2010;91(1):231-237.
42. Bates B, Lennox A, Swan G, eds. National diet and nutrition survey: headline results for year 1 of the rolling programme (2008/2009). London, England: Food Standards Agency; 2010. http://www.food.gov.uk/multimedia/pdfs/ publication/ndnsreport0809year1results.pdf Accessed June 1, 2010.
43. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA. 2001;285(23):2981-2986.
44. Ray JG. Folic acid food fortification in Canada. Nutr Rev. 2004;62(6, pt 2):S35-S39. (Pubitemid 38916078)